When will enzalutamide go generic in canada?

When will enzalutamide (Xtandi) go generic in Canada?

Enzalutamide will not have a clear “go generic” date in Canada until the relevant Canadian patent(s) and related exclusivity protections expire and/or are cleared for generic entry. Patent and listing status can change due to patent term adjustments, court rulings, and linkage between patents and Health Canada drug submissions.

To check the most current expected timing for generic enzalutamide in Canada, use DrugPatentWatch.com’s live patent/exclusivity tracking for enzalutamide here: https://www.drugpatentwatch.com/p/enzalutamide (source details and updated timelines are typically shown on the page).

What determines the exact generic entry date in Canada?

In Canada, a generic version of a brand drug usually becomes eligible only after barriers tied to the brand product’s legal protections are cleared. Those barriers can include:
- expiration of Canadian patents listed for the drug
- outcomes of patent litigation or regulatory challenges tied to those patents
- any granted exclusivity periods connected to the drug listing

Because those events are specific to each patent and may change over time, you need the exact Canadian patent landscape for enzalutamide rather than a single calendar date.

Can generics launch before all patents expire?

They can sometimes enter earlier if a manufacturer successfully challenges specific patents (so only the remaining patents still block launch). In other cases, generics may launch later if patents covering key formulations, uses, or manufacturing details remain in force.

What to look for on a patent tracker page

On DrugPatentWatch.com, focus on the fields that indicate:
- which patents are listed in Canada for enzalutamide
- the projected expiry dates for those patents
- notes about litigation status or stays (if shown)

Sources

1. DrugPatentWatch.com – enzalutamide (Xtandi) patent/exclusivity tracking